疫苗产品创新策略:为中低收入国家产品开发与采纳创造有利环境
为推进免疫议程2030和Gavi 5.0策略,VIPS于2020年优先选出微阵列贴片、热稳定及控温链液体疫苗配方和初级包装条形码三项创新。作者分析四个已上市疫苗产品创新并访谈17个免疫组织及独立专家,提出「创新困局」与疫苗产品创新「变革理论」,强调产品开发同时需采取行动激励可持续投资并铺就采纳路径。
要点
- VIPS优先三项创新:微阵列贴片、热稳定及控温链液体疫苗配方、初级包装条形码。
- 优先依据为资源受限环境免疫障碍及对健康、覆盖、公平、安全、经济成本、技术成熟度和商业可行性的潜在影响。
- 产品开发需并行开展激励可持续投资和准备采纳路径的行动。
核心结论
- VIPS正加速三项优先疫苗产品创新的开发,并为未来采纳奠定基础,长期目标是确保中低收入国家公平疫苗覆盖并提升疫苗影响。
研究设计与样本
- 分析四个已上市疫苗产品创新,并访谈来自17个免疫组织和/或独立免疫专家。
主要发现
- 研究结果归纳为描述疫苗产品创新开发挑战的「创新困局」和疫苗产品创新「变革理论」。
- 变革理论强调应与产品开发并行采取行动以激励可持续投资并准备采纳与影响路径。
关键数值与推荐
- 2020年VIPS优先三项创新:微阵列贴片(MAPs)、热稳定和控温链(CTC)液体疫苗配方、初级包装条形码。
- 优先基于资源受限背景下可能克服的优先免疫障碍,并考虑对健康、覆盖和公平、安全、经济成本及技术准备和商业可行性的潜在影响。
临床怎么用
- 为中低收入国家疫苗产品创新的开发与采纳提供策略框架,指导并行开展投资激励与采纳准备。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine-product innovations that address barriers to immunization are urgently needed to achieve equitable vaccine coverage, as articulated in the new Immunization Agenda 2030 and the Gavi 5.0 strategy. In 2020, the Vaccine Innovation Prioritisation Strategy (VIPS) prioritized three innovations, namely microarray patches (MAPs), heat-stable and controlled-temperature chain (CTC) enabled liquid vaccine formulations and barcodes on primary packaging. These innovations were prioritized based on the priority immunization barriers that they may help overcome in resource constrained contexts, as well as by considering their potential impact on health, coverage and equity, safety, economic costs and their technical readiness and commercial feasibility. VIPS is now working to accelerate the development and lay the foundation for future uptake of the three priority vaccine-product innovations, with the long term-goal to ensure equitable vaccine coverage and increased impact of vaccines in low- and middle- income countries. To inform our strategic planning, we analyzed four commercially available vaccine product-innovations and conducted interviews with individuals from 17 immunization organizations, and/or independent immunization experts. The findings are synthesized into an 'innovation conundrum' that describes the challenges encountered in developing vaccine-product innovations and a vaccine-product innovation 'theory of change', which highlights actions that should be undertaken in parallel to product development to incentivize sustainable investment and prepare the pathway for uptake and impact.
引用
- Giersing B, Shah N, Kristensen D, et al. Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries. Vaccine. 2021. PMID: 34627624. doi:10.1016/j.vaccine.2021.07.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。